Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
GSK plc logo

NASDAQ · GSK

GSK plc

Healthcare · Drug Manufacturers - General

$50.22

Down-$0.84 (-1.65%)

Updated Sep 20, 2026, 10:02 AM

SID Score

6.5/10

Composite research score

Smart Money

56/100

Neutral

Market cap
99.39B
P/E ratio
13.41
Dividend yield
3.34%
52-week range
$39.29 – $61.70
Volume
4.71M
Avg. volume
5.18M

Price performance

GSK price history

1M range · 19 trading sessions · Daily adjusted prices

GSK closed at $50.22 after 19 trading sessions, down 3.01% for the selected period.

Last close
$50.22
Period change
-3.01%
Period low
$48.12
Period high
$52.07
Daily close
View OHLC price history
GSK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 18, 2026$50.20$50.33$49.50$50.224.71M
Sep 17, 2026$50.72$51.075$50.62$51.063.08M
Sep 16, 2026$50.19$50.71$50.055$50.292.84M
Sep 15, 2026$49.69$50.155$49.63$50.012.74M
Sep 14, 2026$50.29$50.30$49.61$50.053M
Sep 11, 2026$48.70$48.80$47.85$48.132.28M
Sep 10, 2026$48.47$48.59$47.975$48.122.15M
Sep 9, 2026$48.815$49.16$48.60$48.632.41M
Sep 8, 2026$49.00$49.2349$48.54$48.543.06M
Sep 4, 2026$49.70$50.06$49.66$49.892.29M
Sep 3, 2026$51.50$51.52$50.19$50.872.44M
Sep 2, 2026$50.36$51.08$50.04$50.442.94M
Sep 1, 2026$51.11$51.26$50.465$50.663.27M
Aug 31, 2026$50.62$50.82$50.25$50.252.39M
Aug 28, 2026$50.22$50.88$49.95$50.823.43M
Aug 27, 2026$50.945$51.03$50.165$50.272.47M
Aug 26, 2026$51.90$52.09$51.40$51.431.72M
Aug 25, 2026$51.57$52.21$51.51$52.072.7M
Aug 24, 2026$51.54$51.9491$51.40$51.782.89M

Latest GSK news

The latest Smart Investors Daily articles mentioning GSK.

Stock researchCompany · Overview

GSK research

Overview

Company profile and research snapshot.

Company profile

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$53.00
Implied upside
—
Analysts
7
GSK recent ratings
DateFirmRatingTarget
Jun 8, 2026DeutscheHold—
May 28, 2026JefferiesBuy—
May 27, 2026DeutscheHold—
May 6, 2026DeutscheHold—
May 6, 2026CitigroupNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 17, 2026

ViiV Healthcare Partners with Prevention Access Campaign (PAC) to Celebrate 10 Years of U=U and Look to The Future

DURHAM, N.C., September 17, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced the continuation of its long-standing partnership with Prevention Access Campaign (PAC) – the founding organization behind the Undetectable = Untransmittable (U=U) movement. To celebrate 10 years of U=U, ViiV Healthcare is joining PAC to introduce "Undetectable Voices," a new digital storytelling and community engagement campaign that builds

Yahoo · Sep 17, 2026

GSK (LSE:GSK) Stock Looks Reasonable As Its 58% Run Continues

GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a simple question for investors who care about valuation. Is the current price you see on screen today adequately supported by the earnings power of the business? Over the past 5 years GSK shares have returned 58.4%, which puts real weight on whether the current earnings justify where the stock now trades. Recent deals in cancer therapies, including new T cell engager and...

Yahoo · Sep 17, 2026

GSK (LSE:GSK) Agrees Multiple Myeloma T Cell Deal

GSK (LSE:GSK) agreed to acquire Chimagen's trispecific T cell-engager candidate for multiple myeloma, expanding its blood cancer research portfolio. The drug asset is described by the parties as a potential best in class trispecific T cell therapy targeting multiple myeloma. GSK plans to close its German vaccine manufacturing site and consolidate production in Canada, with associated job reductions and supply chain changes. The acquisition of Chimagen's trispecific T cell-engager and the...

Yahoo · Sep 16, 2026

GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline

GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of internal research and business development, according to Hesham Abdullah, the company’s senior vice pre

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By